Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Jounce Therapeutics Trading Up 3.4 %
Shares of NASDAQ:JNCE traded up $0.16 during mid-day trading on Monday, reaching $4.87. The stock had a trading volume of 97,531 shares, compared to its average volume of 344,412. The company has a market cap of $251.75 million, a P/E ratio of -1.91 and a beta of 1.17. Jounce Therapeutics has a 1 year low of $2.76 and a 1 year high of $9.81. The business's 50 day moving average price is $3.42 and its 200 day moving average price is $5.32.
Wall Street Analyst Weigh In
JNCE has been the subject of a number of recent research reports. StockNews.com upgraded Jounce Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, August 5th. Piper Sandler cut their price objective on Jounce Therapeutics from $17.00 to $9.00 and set an "overweight" rating for the company in a report on Monday, May 23rd. Raymond James raised Jounce Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their price target for the company from $15.00 to $20.00 in a report on Friday, May 6th. HC Wainwright cut their price target on Jounce Therapeutics from $15.00 to $11.00 and set a "buy" rating for the company in a report on Friday, August 5th. Finally, Robert W. Baird cut their price target on Jounce Therapeutics to $5.00 in a report on Tuesday, August 9th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $12.40.